Business Context and Reporting Period
Company: Coherus Oncology, Inc. (CHRS)
Filing Type: Form 8-K (Current Report)
Date of Report: February 4, 2026
Event: Announcement of a clinical supply agreement with Janssen Research & Development, LLC.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not contain financial statements. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the execution of a strategic collaboration to advance clinical development:
- Agreement: Clinical supply agreement with Janssen Research & Development, LLC.
- Compounds: Coherus's investigational anti-CCR8 cytolytic monoclonal antibody (tagmokitug/CHS-114) in combination with Janssen's T-cell engaging bispecific antibody (pasritamig).
- Study Design: Phase 1b clinical study in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Roles: Janssen will provide pasritamig; Coherus will act as the sponsor of the trial.
- Commercial Rights: Both parties retain all commercial rights to their respective compounds, including as monotherapy or in combination treatments.
Guidance, Outlook, and Risks
Outlook: The agreement facilitates the evaluation of tagmokitug in combination with pasritamig, potentially accelerating the development of this therapeutic approach for mCRPC.
Risks and Contingencies: The filing does not explicitly list risks, contingencies, or unusual items. Standard clinical development risks (e.g., trial delays, efficacy outcomes) apply but are not detailed in this specific text.
Investor Verification Checklist
- Verify the specific terms of the clinical supply agreement regarding timelines and milestones.
- Confirm the current development status of tagmokitug (CHS-114) and pasritamig in other indications.
- Review Coherus's cash runway and capital requirements to sponsor the Phase 1b trial.
- Monitor future updates on patient enrollment and preliminary safety/efficacy data from the mCRPC study.